Two Endogenous Antiangiogenic Inhibitors, Endostatin and Angiostatin, Demonstrate Biphasic Curves in their Antitumor Profiles

Angiogenesis refers to growth of blood vessels from pre-existing ones. In 1971, Folkman proposed that by choking off the blood supply to tumors, they are starved, leading to their demise. A few years ago, the monoclonal antibody Avastin became the first antiangiogenic biological approved by FDA, for...

Full description

Saved in:
Bibliographic Details
Published in:Dose-response 2011-07, Vol.9 (3), p.369-376
Main Authors: Javaherian, Kashi, Lee, Tong-Young, Sjin, Robert M. Tjin Tham, Parris, George E., Hlatky, Lynn
Format: Article
Language:English
Subjects:
Angiogenesis
Cancer therapies
Monoclonal antibodies
Statins
Citations: Items that this one cites
Items that cite this one
Online Access:Get full text
Tags: Add Tag
No Tags, Be the first to tag this record!
cited_by cdi_FETCH-LOGICAL-c587t-9c4adb8f7fb0aa75765dd3293bc780c7efa3b38a74b642e7ed982981a663b3613
cites cdi_FETCH-LOGICAL-c587t-9c4adb8f7fb0aa75765dd3293bc780c7efa3b38a74b642e7ed982981a663b3613
container_end_page 376
container_issue 3
container_start_page 369
container_title Dose-response
container_volume 9
creator Javaherian, Kashi
Lee, Tong-Young
Sjin, Robert M. Tjin Tham
Parris, George E.
Hlatky, Lynn
description Angiogenesis refers to growth of blood vessels from pre-existing ones. In 1971, Folkman proposed that by choking off the blood supply to tumors, they are starved, leading to their demise. A few years ago, the monoclonal antibody Avastin became the first antiangiogenic biological approved by FDA, for treatment of cancer patients. Two other antiangiogenic endogenous protein fragments were isolated in Folkman's laboratory more than a decade ago. Here, we present a short review of data demonstrating that angiostatin and endostatin display a biphasic antitumor dose-response. This behavior is common among a large number of antiangiogenic agents and the reduced effectiveness of antiangiogenic agents at high dose rates may be due to suppression of growth of new vessels carrying the agent into the critical region around the tumor.
doi_str_mv 10.2203/dose-response.10-020.Javaherian
format article
fullrecord <record><control><sourceid>proquest_doaj_</sourceid><recordid>TN_cdi_doaj_primary_oai_doaj_org_article_0258f5d27ab64e8da98b730a30d0523d</recordid><sourceformat>XML</sourceformat><sourcesystem>PC</sourcesystem><sage_id>10.2203_dose-response.10-020.Javaherian</sage_id><doaj_id>oai_doaj_org_article_0258f5d27ab64e8da98b730a30d0523d</doaj_id><sourcerecordid>2576451435</sourcerecordid><originalsourceid>FETCH-LOGICAL-c587t-9c4adb8f7fb0aa75765dd3293bc780c7efa3b38a74b642e7ed982981a663b3613</originalsourceid><addsrcrecordid>eNqNkk1v1DAQhiMEoqXwF1AkDr00i2PHcSwhUFkKLKoEh3K2JvFk16vE3trOIg78d7y7_eTEyfHk8aPx-M2y05LMKCXsrXYBC49h42zAWUkKQsnsG2xhhd6AfZIdl5zLglHePH3wfZS9CGFNSMUFK59nR8lVMiblcfbn6pfLL6x2S7RuCvm5jcmzNLu96fKFXZnWROfD2Z4KEaKxOVidyEQd9mf5JxxTR9FDxPyj2awgpMPzyW8x5ImPKzR-747T6Hz-w7veDBheZs96GAK-ullPsp-fL67mX4vL718W8_PLouONiIXsKtBt04u-JQCCi5przahkbSca0gnsgbWsAVG1dUVRoJYNlU0JdZ3qdclOssXBqx2s1cabEfxv5cCofcH5pQIfTTegImlcPddUQHJho0E2rWAEGNGEU6aT6_3BtZnaEXWHNl17eCR9_MealVq6rWJlU0u2a-b0RuDd9YQhqtGEDocBLKYnUJKQmgoiaSLf_EOu3eRtmpSiaQgVLyvGE_XhQHXeheCxv-ulJGqXGrVLjbpNza6aUqPuU5MMrx9e6e78bUwS8O4ABFjifRP_6_8LZEHeyQ</addsrcrecordid><sourcetype>Open Website</sourcetype><iscdi>true</iscdi><recordtype>article</recordtype><pqid>2576451435</pqid></control><display><type>article</type><title>Two Endogenous Antiangiogenic Inhibitors, Endostatin and Angiostatin, Demonstrate Biphasic Curves in their Antitumor Profiles</title><source>SAGE Open Access</source><source>Publicly Available Content (ProQuest)</source><source>PubMed Central</source><creator>Javaherian, Kashi ; Lee, Tong-Young ; Sjin, Robert M. Tjin Tham ; Parris, George E. ; Hlatky, Lynn</creator><creatorcontrib>Javaherian, Kashi ; Lee, Tong-Young ; Sjin, Robert M. Tjin Tham ; Parris, George E. ; Hlatky, Lynn</creatorcontrib><description>Angiogenesis refers to growth of blood vessels from pre-existing ones. In 1971, Folkman proposed that by choking off the blood supply to tumors, they are starved, leading to their demise. A few years ago, the monoclonal antibody Avastin became the first antiangiogenic biological approved by FDA, for treatment of cancer patients. Two other antiangiogenic endogenous protein fragments were isolated in Folkman's laboratory more than a decade ago. Here, we present a short review of data demonstrating that angiostatin and endostatin display a biphasic antitumor dose-response. This behavior is common among a large number of antiangiogenic agents and the reduced effectiveness of antiangiogenic agents at high dose rates may be due to suppression of growth of new vessels carrying the agent into the critical region around the tumor.</description><identifier>ISSN: 1559-3258</identifier><identifier>EISSN: 1559-3258</identifier><identifier>DOI: 10.2203/dose-response.10-020.Javaherian</identifier><identifier>PMID: 22013399</identifier><language>eng</language><publisher>Los Angeles, CA: SAGE Publications</publisher><subject>Angiogenesis ; Cancer therapies ; Monoclonal antibodies ; Statins</subject><ispartof>Dose-response, 2011-07, Vol.9 (3), p.369-376</ispartof><rights>2011 University of Massachusetts</rights><rights>2011 University of Massachusetts. This work is licensed under the Creative Commons Attribution – Non-Commercial License http://creativecommons.org/licenses/by-nc/3.0/ (the “License”). Notwithstanding the ProQuest Terms and Conditions, you may use this content in accordance with the terms of the License.</rights><rights>Copyright © 2011 University of Massachusetts 2011</rights><lds50>peer_reviewed</lds50><oa>free_for_read</oa><woscitedreferencessubscribed>false</woscitedreferencessubscribed><citedby>FETCH-LOGICAL-c587t-9c4adb8f7fb0aa75765dd3293bc780c7efa3b38a74b642e7ed982981a663b3613</citedby><cites>FETCH-LOGICAL-c587t-9c4adb8f7fb0aa75765dd3293bc780c7efa3b38a74b642e7ed982981a663b3613</cites></display><links><openurl>$$Topenurl_article</openurl><openurlfulltext>$$Topenurlfull_article</openurlfulltext><thumbnail>$$Tsyndetics_thumb_exl</thumbnail><linktopdf>$$Uhttps://www.ncbi.nlm.nih.gov/pmc/articles/PMC3186931/pdf/$$EPDF$$P50$$Gpubmedcentral$$H</linktopdf><linktohtml>$$Uhttps://www.proquest.com/docview/2576451435?pq-origsite=primo$$EHTML$$P50$$Gproquest$$Hfree_for_read</linktohtml><link.rule.ids>230,314,727,780,784,885,21966,25753,27853,27924,27925,37012,37013,44590,44945,45333,53791,53793</link.rule.ids><backlink>$$Uhttps://www.ncbi.nlm.nih.gov/pubmed/22013399$$D View this record in MEDLINE/PubMed$$Hfree_for_read</backlink></links><search><creatorcontrib>Javaherian, Kashi</creatorcontrib><creatorcontrib>Lee, Tong-Young</creatorcontrib><creatorcontrib>Sjin, Robert M. Tjin Tham</creatorcontrib><creatorcontrib>Parris, George E.</creatorcontrib><creatorcontrib>Hlatky, Lynn</creatorcontrib><title>Two Endogenous Antiangiogenic Inhibitors, Endostatin and Angiostatin, Demonstrate Biphasic Curves in their Antitumor Profiles</title><title>Dose-response</title><addtitle>Dose Response</addtitle><description>Angiogenesis refers to growth of blood vessels from pre-existing ones. In 1971, Folkman proposed that by choking off the blood supply to tumors, they are starved, leading to their demise. A few years ago, the monoclonal antibody Avastin became the first antiangiogenic biological approved by FDA, for treatment of cancer patients. Two other antiangiogenic endogenous protein fragments were isolated in Folkman's laboratory more than a decade ago. Here, we present a short review of data demonstrating that angiostatin and endostatin display a biphasic antitumor dose-response. This behavior is common among a large number of antiangiogenic agents and the reduced effectiveness of antiangiogenic agents at high dose rates may be due to suppression of growth of new vessels carrying the agent into the critical region around the tumor.</description><subject>Angiogenesis</subject><subject>Cancer therapies</subject><subject>Monoclonal antibodies</subject><subject>Statins</subject><issn>1559-3258</issn><issn>1559-3258</issn><fulltext>true</fulltext><rsrctype>article</rsrctype><creationdate>2011</creationdate><recordtype>article</recordtype><sourceid>AFRWT</sourceid><sourceid>PIMPY</sourceid><sourceid>DOA</sourceid><recordid>eNqNkk1v1DAQhiMEoqXwF1AkDr00i2PHcSwhUFkKLKoEh3K2JvFk16vE3trOIg78d7y7_eTEyfHk8aPx-M2y05LMKCXsrXYBC49h42zAWUkKQsnsG2xhhd6AfZIdl5zLglHePH3wfZS9CGFNSMUFK59nR8lVMiblcfbn6pfLL6x2S7RuCvm5jcmzNLu96fKFXZnWROfD2Z4KEaKxOVidyEQd9mf5JxxTR9FDxPyj2awgpMPzyW8x5ImPKzR-747T6Hz-w7veDBheZs96GAK-ullPsp-fL67mX4vL718W8_PLouONiIXsKtBt04u-JQCCi5przahkbSca0gnsgbWsAVG1dUVRoJYNlU0JdZ3qdclOssXBqx2s1cabEfxv5cCofcH5pQIfTTegImlcPddUQHJho0E2rWAEGNGEU6aT6_3BtZnaEXWHNl17eCR9_MealVq6rWJlU0u2a-b0RuDd9YQhqtGEDocBLKYnUJKQmgoiaSLf_EOu3eRtmpSiaQgVLyvGE_XhQHXeheCxv-ulJGqXGrVLjbpNza6aUqPuU5MMrx9e6e78bUwS8O4ABFjifRP_6_8LZEHeyQ</recordid><startdate>20110701</startdate><enddate>20110701</enddate><creator>Javaherian, Kashi</creator><creator>Lee, Tong-Young</creator><creator>Sjin, Robert M. Tjin Tham</creator><creator>Parris, George E.</creator><creator>Hlatky, Lynn</creator><general>SAGE Publications</general><general>SAGE PUBLICATIONS, INC</general><general>International Hormesis Society</general><general>SAGE Publishing</general><scope>AFRWT</scope><scope>NPM</scope><scope>AAYXX</scope><scope>CITATION</scope><scope>3V.</scope><scope>7X7</scope><scope>7XB</scope><scope>8FI</scope><scope>8FJ</scope><scope>8FK</scope><scope>ABUWG</scope><scope>AFKRA</scope><scope>AZQEC</scope><scope>BENPR</scope><scope>CCPQU</scope><scope>DWQXO</scope><scope>FYUFA</scope><scope>GHDGH</scope><scope>K9.</scope><scope>M0S</scope><scope>PIMPY</scope><scope>PQEST</scope><scope>PQQKQ</scope><scope>PQUKI</scope><scope>PRINS</scope><scope>7X8</scope><scope>5PM</scope><scope>DOA</scope></search><sort><creationdate>20110701</creationdate><title>Two Endogenous Antiangiogenic Inhibitors, Endostatin and Angiostatin, Demonstrate Biphasic Curves in their Antitumor Profiles</title><author>Javaherian, Kashi ; Lee, Tong-Young ; Sjin, Robert M. Tjin Tham ; Parris, George E. ; Hlatky, Lynn</author></sort><facets><frbrtype>5</frbrtype><frbrgroupid>cdi_FETCH-LOGICAL-c587t-9c4adb8f7fb0aa75765dd3293bc780c7efa3b38a74b642e7ed982981a663b3613</frbrgroupid><rsrctype>articles</rsrctype><prefilter>articles</prefilter><language>eng</language><creationdate>2011</creationdate><topic>Angiogenesis</topic><topic>Cancer therapies</topic><topic>Monoclonal antibodies</topic><topic>Statins</topic><toplevel>peer_reviewed</toplevel><toplevel>online_resources</toplevel><creatorcontrib>Javaherian, Kashi</creatorcontrib><creatorcontrib>Lee, Tong-Young</creatorcontrib><creatorcontrib>Sjin, Robert M. Tjin Tham</creatorcontrib><creatorcontrib>Parris, George E.</creatorcontrib><creatorcontrib>Hlatky, Lynn</creatorcontrib><collection>SAGE Open Access</collection><collection>PubMed</collection><collection>CrossRef</collection><collection>ProQuest Central (Corporate)</collection><collection>ProQuest Health &amp; Medical Collection</collection><collection>ProQuest Central (purchase pre-March 2016)</collection><collection>Hospital Premium Collection</collection><collection>Hospital Premium Collection (Alumni Edition)</collection><collection>ProQuest Central (Alumni) (purchase pre-March 2016)</collection><collection>ProQuest Central (Alumni)</collection><collection>ProQuest Central</collection><collection>ProQuest Central Essentials</collection><collection>AUTh Library subscriptions: ProQuest Central</collection><collection>ProQuest One Community College</collection><collection>ProQuest Central</collection><collection>Health Research Premium Collection</collection><collection>Health Research Premium Collection (Alumni)</collection><collection>ProQuest Health &amp; Medical Complete (Alumni)</collection><collection>Health &amp; Medical Collection (Alumni Edition)</collection><collection>Publicly Available Content (ProQuest)</collection><collection>ProQuest One Academic Eastern Edition (DO NOT USE)</collection><collection>ProQuest One Academic</collection><collection>ProQuest One Academic UKI Edition</collection><collection>ProQuest Central China</collection><collection>MEDLINE - Academic</collection><collection>PubMed Central (Full Participant titles)</collection><collection>DOAJ Directory of Open Access Journals</collection><jtitle>Dose-response</jtitle></facets><delivery><delcategory>Remote Search Resource</delcategory><fulltext>fulltext</fulltext></delivery><addata><au>Javaherian, Kashi</au><au>Lee, Tong-Young</au><au>Sjin, Robert M. Tjin Tham</au><au>Parris, George E.</au><au>Hlatky, Lynn</au><format>journal</format><genre>article</genre><ristype>JOUR</ristype><atitle>Two Endogenous Antiangiogenic Inhibitors, Endostatin and Angiostatin, Demonstrate Biphasic Curves in their Antitumor Profiles</atitle><jtitle>Dose-response</jtitle><addtitle>Dose Response</addtitle><date>2011-07-01</date><risdate>2011</risdate><volume>9</volume><issue>3</issue><spage>369</spage><epage>376</epage><pages>369-376</pages><issn>1559-3258</issn><eissn>1559-3258</eissn><abstract>Angiogenesis refers to growth of blood vessels from pre-existing ones. In 1971, Folkman proposed that by choking off the blood supply to tumors, they are starved, leading to their demise. A few years ago, the monoclonal antibody Avastin became the first antiangiogenic biological approved by FDA, for treatment of cancer patients. Two other antiangiogenic endogenous protein fragments were isolated in Folkman's laboratory more than a decade ago. Here, we present a short review of data demonstrating that angiostatin and endostatin display a biphasic antitumor dose-response. This behavior is common among a large number of antiangiogenic agents and the reduced effectiveness of antiangiogenic agents at high dose rates may be due to suppression of growth of new vessels carrying the agent into the critical region around the tumor.</abstract><cop>Los Angeles, CA</cop><pub>SAGE Publications</pub><pmid>22013399</pmid><doi>10.2203/dose-response.10-020.Javaherian</doi><tpages>8</tpages><oa>free_for_read</oa></addata></record>
fulltext fulltext
identifier ISSN: 1559-3258
ispartof Dose-response, 2011-07, Vol.9 (3), p.369-376
issn 1559-3258
1559-3258
language eng
recordid cdi_doaj_primary_oai_doaj_org_article_0258f5d27ab64e8da98b730a30d0523d
source SAGE Open Access; Publicly Available Content (ProQuest); PubMed Central
subjects Angiogenesis
Cancer therapies
Monoclonal antibodies
Statins
title Two Endogenous Antiangiogenic Inhibitors, Endostatin and Angiostatin, Demonstrate Biphasic Curves in their Antitumor Profiles
url http://sfxeu10.hosted.exlibrisgroup.com/loughborough?ctx_ver=Z39.88-2004&ctx_enc=info:ofi/enc:UTF-8&ctx_tim=2025-01-07T23%3A30%3A22IST&url_ver=Z39.88-2004&url_ctx_fmt=infofi/fmt:kev:mtx:ctx&rfr_id=info:sid/primo.exlibrisgroup.com:primo3-Article-proquest_doaj_&rft_val_fmt=info:ofi/fmt:kev:mtx:journal&rft.genre=article&rft.atitle=Two%20Endogenous%20Antiangiogenic%20Inhibitors,%20Endostatin%20and%20Angiostatin,%20Demonstrate%20Biphasic%20Curves%20in%20their%20Antitumor%20Profiles&rft.jtitle=Dose-response&rft.au=Javaherian,%20Kashi&rft.date=2011-07-01&rft.volume=9&rft.issue=3&rft.spage=369&rft.epage=376&rft.pages=369-376&rft.issn=1559-3258&rft.eissn=1559-3258&rft_id=info:doi/10.2203/dose-response.10-020.Javaherian&rft_dat=%3Cproquest_doaj_%3E2576451435%3C/proquest_doaj_%3E%3Cgrp_id%3Ecdi_FETCH-LOGICAL-c587t-9c4adb8f7fb0aa75765dd3293bc780c7efa3b38a74b642e7ed982981a663b3613%3C/grp_id%3E%3Coa%3E%3C/oa%3E%3Curl%3E%3C/url%3E&rft_id=info:oai/&rft_pqid=2576451435&rft_id=info:pmid/22013399&rft_sage_id=10.2203_dose-response.10-020.Javaherian&rfr_iscdi=true